Search Results - "Aboagye, Jeremy"

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial by Madhavan, Meera, Ritchie, Adam J., Aboagye, Jeremy, Jenkin, Daniel, Provstgaad-Morys, Samuel, Tarbet, Iona, Woods, Danielle, Davies, Sophie, Baker, Megan, Platt, Abigail, Flaxman, Amy, Smith, Holly, Belij-Rammerstorfer, Sandra, Wilkins, Deidre, Kelly, Elizabeth J., Villafana, Tonya, Green, Justin A., Poulton, Ian, Lambe, Teresa, Hill, Adrian V.S., Ewer, Katie J., Douglas, Alexander D.

“…Intranasal vaccination may induce protective local and systemic immune responses against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine…”
Get full text

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial by Bosaeed, Mohammad, Balkhy, Hanan H, Almaziad, Sultan, Aljami, Haya A, Alhatmi, Hind, Alanazi, Hala, Alahmadi, Mashael, Jawhary, Ayah, Alenazi, Mohammed W, Almasoud, Abdulrahman, Alanazi, Rawan, Bittaye, Mustapha, Aboagye, Jeremy, Albaalharith, Nahla, Batawi, Sarah, Folegatti, Pedro, Ramos Lopez, Fernando, Ewer, Katie, Almoaikel, Khalid, Aljeraisy, Majed, Alothman, Adel, Gilbert, Sarah C, Khalaf Alharbi, Naif

“…ChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been licensed for…”
Get full text

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya by Sang, Samuel, Datoo, Mehreen S, Otieno, Edward, Muiruri, Charles, Bellamy, Duncan, Gathuri, Emmaloise, Ngoto, Omar, Musembi, Janet, Provstgaard-Morys, Sam, Stockdale, Lisa, Aboagye, Jeremy, Woods, Daniel, Lawrie, Alison, Roberts, Racheal, Keter, Kelvias, Kimani, Domtila, Ndungu, Francis, Kapulu, Melissa, Njau, Irene, Orindi, Benedict, Ewer, Katie J, Hill, Adrian V S, Bejon, Philip, Hamaluba, Mainga

“…Falciparum malaria remains a global health problem. Two vaccines, based on the circumsporozoite antigen, are available. RTS, S/AS01 was recommended for use in…”
Get full text

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies by Folegatti, Pedro M, Flaxman, Amy, Jenkin, Daniel, Makinson, Rebecca, Kingham-Page, Lucy, Bellamy, Duncan, Ramos Lopez, Fernando, Sheridan, Jonathan, Poulton, Ian, Aboagye, Jeremy, Tran, Nguyen, Mitton, Celia, Roberts, Rachel, Lawrie, Alison M, Hill, Adrian V S, Ewer, Katie J, Gilbert, Sarah

“…Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and…”
Get full text

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial by Datoo, Mehreen S, Natama, Hamtandi Magloire, Somé, Athanase, Bellamy, Duncan, Traoré, Ousmane, Rouamba, Toussaint, Tahita, Marc Christian, Ido, N Félix André, Yameogo, Prisca, Valia, Daniel, Millogo, Aida, Ouedraogo, Florence, Soma, Rachidatou, Sawadogo, Seydou, Sorgho, Faizatou, Derra, Karim, Rouamba, Eli, Ramos-Lopez, Fernando, Cairns, Matthew, Provstgaard-Morys, Samuel, Aboagye, Jeremy, Lawrie, Alison, Roberts, Rachel, Valéa, Innocent, Sorgho, Hermann, Williams, Nicola, Glenn, Gregory, Fries, Louis, Reimer, Jenny, Ewer, Katie J, Shaligram, Umesh, Hill, Adrian V S, Tinto, Halidou

“…Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the…”
Get full text

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study by Schmit, Nora, Topazian, Hillary M, Natama, H Magloire, Bellamy, Duncan, Traoré, Ousmane, Somé, M Athanase, Rouamba, Toussaint, Tahita, Marc Christian, Bonko, Massa dit Achille, Sourabié, Aboubakary, Sorgho, Hermann, Stockdale, Lisa, Provstgaard-Morys, Samuel, Aboagye, Jeremy, Woods, Danielle, Rapi, Katerina, Datoo, Mehreen S, Lopez, Fernando Ramos, Charles, Giovanni D, McCain, Kelly, Ouedraogo, Jean-Bosco, Hamaluba, Mainga, Olotu, Ally, Dicko, Alassane, Tinto, Halidou, Hill, Adrian V S, Ewer, Katie J, Ghani, Azra C, Winskill, Peter

“…The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we…”
Get full text

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials by Voysey, Merryn, Flaxman, Amy, Aboagye, Jeremy, Aley, Parvinder K, Belij-Rammerstorfer, Sandra, Bibi, Sagida, Bittaye, Mustapha, Cappuccini, Federica, Charlton, Sue, Clutterbuck, Elizabeth A, Davies, Sophie, Dold, Christina, Edwards, Nick J, Ewer, Katie J, Faust, Saul N, Folegatti, Pedro M, Fowler, Jamie, Gilbride, Ciaran, Gilbert, Sarah C, Godfrey, Leila, Hallis, Bassam, Humphries, Holly E, Jenkin, Daniel, Kerridge, Simon, Mujadidi, Yama F, Plested, Emma, Ramasamy, Maheshi N, Robinson, Hannah, Sanders, Helen, Snape, Matthew D, Song, Rinn, Thomas, Kelly M, Ulaszewska, Marta, Woods, Danielle, Wright, Daniel, Pollard, Andrew J, Lambe, Teresa

“…Abstract The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on…”
Get full text

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial by Jenkin, Daniel, Ritchie, Adam J, Aboagye, Jeremy, Fedosyuk, Sofiya, Thorley, Luke, Provstgaad-Morys, Samuel, Sanders, Helen, Bellamy, Duncan, Makinson, Rebecca, Xiang, Zhi Quan, Bolam, Emma, Tarrant, Richard, Ramos Lopez, Fernando, Platt, Abigail, Poulton, Ian, Green, Catherine, Ertl, Hildegund C J, Ewer, Katie J, Douglas, Alexander D

“…Rabies kills around 60 000 people each year. ChAdOx2 RabG, a simian adenovirus-vectored rabies vaccine candidate, might have potential to provide low-cost…”
Get full text